The frequency of adverse reactions listed below was determined in the following grades: very often (≥ 10%); often (from ≥ 1% to <10%); infrequently (from ≥ 0.1% to <1%); rarely (from ≥ 0.01% to <0.1%); very rarely (from <0.1%, including individual messages).
Disturbances from the nervous system:
often - increased fatigue, asthenia, dizziness, headache. Usually, these phenomena are of an easy nature and usually take place within 1-2 weeks after the start of treatment;
infrequently - sleep disorders, depression;
rarely - nightmares, hallucinations.
Heart Disease:
very often bradycardia;
infrequently infringement AV conduction (up to the development of complete transverse blockade and cardiac arrest), arrhythmias, worsening of CHF flow with the development of peripheral edema (swelling of the ankles, feet), dyspnea.
Vascular disorders:
often marked decrease in blood pressure (especially in patients with CHF), manifestation of angiospasm (increased peripheral circulatory disturbances, sensation of coldness in the extremities (paresthesia));
infrequently - orthostatic hypotension.
Disorders from the gastrointestinal tract:
often - nausea, vomiting, diarrhea, abdominal pain, constipation, dryness of the oral mucosa;
rarely - a change in taste.
Disorders from the liver and bile ducts:
rarely - hepatitis, increased activity of liver enzymes (alanine aminotransferase, aspartate aminotransferase), increased bilirubin concentration.
Disturbances from the respiratory system, chest and mediastinal organs:
infrequently - laryngo- and bronchospasm in patients with bronchial asthma or obstructive airway disease;
rarely - allergic rhinitis, nasal congestion.
Disturbances from the musculoskeletal and connective tissue:
infrequently - muscle weakness, cramps in the calf muscles, arthralgia.
Disorders from the side of the organ of vision:
rarely - impaired vision, reduced tearing (should be considered when wearing contact lenses);
very rarely - dryness and soreness of the eyes, conjunctivitis.
Hearing disorders and labyrinthine disturbances:
rarely - hearing impairment.
Disturbances from the skin and subcutaneous tissues:
rarely - increased sweating, allergic reactions (skin hyperemia, skin itching, skin rash, urticaria), psoriasis-like skin reactions;
very rarely - alopecia, exacerbation of psoriasis.
Disorders from the endocrine system:
rarely - an increase in the concentration of triglycerides in the blood, hypoglycemia.
Disorders from the genitourinary system:
rarely - a violation of potency, a weakening of the libido.
Immune system disorders:
rarely - the emergence of antinuclear antibodies with unusual clinical symptoms of lupus-like syndrome, which disappear with the end of treatment.
Laboratory and instrumental data:
rarely - an increase in the concentration of triglycerides in the blood;
very rarely - thrombocytopenia, agranulocytosis, leukopenia.
Influence on the fetus: intrauterine growth retardation, hypoglycemia, bradycardia.
General disorders:
very rarely - withdrawal syndrome (increased angina attacks, increased blood pressure).